TNFRSF10B and osteosarcoma: Pishas et al. (2013).  Evaluated the efficacy of drozitumab, a human monoclonal agonistic antibody against DR5, as a novel therapeutic avenue for the targeted treatment of bone and soft tissue sarcomas. Because DR5 is highly expressed on the cell surface of primary osteosarcoma and soft tissue sarcoma (Gamie et al., 2024), targeting DR5 in combination with other antitumor agents has become a promising strategy for the treatment of bone tumors and soft tissue sarcomas.